What Does It Mean for Cyborgs to Be Real Today
Cyborgs are real in the sense that humans already use implanted and wearable devices to restore, enhance, or monitor biological functions. The global human augmentation market, valued at around $3.5 billion in 2024, includes neuroprosthetics, cochlear implants, retinal implants, brain-computer interfaces, and smart prosthetics. Companies such as Neuralink, Synchron, BrainGate consortium members, Ottobock, Össur, and Cochlear are commercializing systems that blur the line between biology and machine. Regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency have approved dozens of neurostimulation and implantable devices over the past decade, confirming that cyborg-like technologies are already in clinical and consumer use.
The definition of a cyborg has shifted from science fiction to a measurable engineering and medical category. A person with a cardiac pacemaker, a cochlear implant, or a closed-loop insulin pump is functionally a cyborg because an external or implanted system continuously senses and actuates on the body. In 2023, the International Federation of Robotics reported more than 1.5 million industrial and medical robotic systems deployed globally, many of which interface directly with human physiology. The U.S. Department of Defense and DARPA have funded programs such as the Neural Engineering System Design and the Bridging the Gap Plus program, which aim to develop high-bandwidth brain-machine interfaces for paralyzed patients, with early human trials showing measurable improvements in communication and mobility.
Leading Companies and Technologies Driving Cyborg Development
Neuralink, founded by Elon Musk and incorporated in Nevada, received FDA approval for its first-in-human clinical trial of the N1 implant in May 2023. The device uses a fully implanted, wireless brain-computer interface with 1,024 electrodes to record neural signals and enable control of external devices. Synchron, a New York-based company, completed the first commercial implantation of its Stentrode brain-computer interface in a U.S. patient in 2022 under a humanitarian device exemption, allowing paralyzed individuals to control digital devices through thought alone. BrainGate, an academic consortium including Brown University and Stanford, has published peer-reviewed results showing that intracortical brain-computer interfaces can enable typing, robotic arm control, and cursor navigation at speeds approaching natural movement.
Beyond neural interfaces, prosthetic and sensory augmentation companies are expanding the cyborg landscape. Össur, an Icelandic orthopedics company, offers bionic knees and feet with powered ankle push-off, while Ottobock, a German medical technology firm, provides myoelectric prosthetic systems with multi-articulating hands and pattern-recognition control. Cochlear, an Australian company, has implanted over 1 million cochlear devices worldwide, making it one of the most successful cyborg technologies in history. In the financial and regulatory space, the SEC filings of publicly traded medical device companies show consistent growth in R&D spending on neural and sensory implants, and the FDA's breakthrough device program has fast-tracked several neuroprosthetic systems since 2020.
Regulation, Market Growth, and the Near-Term Cyborg Economy
The regulatory framework for cyborg technologies is evolving rapidly as implantable and wearable devices proliferate. The FDA classifies most brain-computer interfaces and neurostimulators as Class III medical devices, requiring premarket approval with clinical evidence of safety and effectiveness. In the European Union, the Medical Device Regulation, fully applicable since May 2021, imposes stricter scrutiny on implantable devices, including cybersecurity and post-market surveillance requirements. The U.S. Department of Commerce Bureau of Industry and Security has also updated export controls on advanced neurotechnology, reflecting geopolitical concerns about dual-use brain-computer interface capabilities.
Market data shows strong growth in the human augmentation and cy